Biogen France
Presence
Biogen is one of the...
Biogen is a company listed under the stock ticker BIIB (US).
Biogen has a direct presence in 9 countries.Biogen has 9 subsidiaries including Biogen ANZ, Biogen BeLux and Biogen Canada.
They are in:
Acquisition, funding and merger involving Biogen.
- Biogen has acquired Reata Pharmaceuticals (posted on September 29 2023).
- Biogen has announced the acquisition of Reata Pharmaceuticals (posted on August 1 2023).
Executives
View the org chart displaying its 3 main executives
Most searched biographies at Biogen France
- Jennifer Papandreou, Director, Neuroscience
- Javier Gonzalez, Business Unit Director, Biosimilars
- Elodie Wilmet, Head of Value and Access and Governmental Affairs
Popular executive movements at Biogen
- Maha Radhakrishnan, Group Senior Vice President and Chief Medical Officer, has left the company (posted on March 18 2024).
- Monish Patolawala has joined the company as Director (posted on November 7 2023).
- Jane Grogan will join the company as Executive Vice President and Head of Research on Oct. 2, 2023 (posted on September 7 2023).
Create your alert
to follow the executive moves at Biogen France.
Biotechnology
Biogen has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Biogen France
- EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 | Biogen
- The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus | Biogen
- FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS | Biogen
- Biogen to Report Second Quarter 2022 Financial Results July 20, 2022 | Biogen
- The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway | Biogen
- Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform | Biogen
- European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) | Biogen
- New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) | Biogen
- The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities | Biogen
- Biogen Withdrawal from the Jefferies Healthcare Conference | Biogen
- View more press releases Close
Social media about Biogen France
- Biogen France on Wikipedia, Google News & Yahoo Finance
- Biogen France on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Javier Gonzalez 
Call Biogen France at +33 14...
